RxDoctor Payments DataLook up a doctor →

Clarene Hansen

Nurse Practitioner · Provo, UTNPI 1114985553

Payments from drug & device makers

$11,307in general payments, 2019–2025

Across 611 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$619
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$1,31112%
  • Food & beverage$9,98388%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,307 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$103,681
Medicare patients
304
Services billed
3,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$314,890
JardianceEmpagliflozin208$267,836
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog216$210,527
MounjaroTirzepatide125$153,650
TrulicityDulaglutide89$114,758
Tresiba Flextouch U-100Insulin Degludec91$102,944
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog77$85,166
FarxigaDapagliflozin Propanediol66$50,102
Novolog FlexpenInsulin Aspart133$41,598
Lantus SolostarInsulin Glargine,hum.Rec.Anlog160$36,711
Humalog Kwikpen U-100Insulin Lispro86$36,055
Tresiba Flextouch U-200Insulin Degludec23$34,517
TymlosAbaloparatide12$31,364
Lyumjev Kwikpen U-100Insulin Lispro-Aabc34$29,820
Victoza 3-PakLiraglutide20$25,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$1,230$333,916258 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$1,372$287,450281 claims
Boehringer IngelheimJardiance$619$267,836208 claims
AstraZenecaFarxiga$1,024$50,10266 claims
Radius Health, Inc.Tymlos$54$31,36412 claims
Sanofi-aventis U.S. LLCLantus$355$12,26455 claims
AbbVieSynthroid$1,125$4,57061 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →